Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATATcH in Advanced Lung or Head and Neck Cancers
NCT05358548Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Apr 2022
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in lung cancer, head and neck cancer (HNC), sponsored by Rutgers University. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
lung cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05358548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358548.